24P Is molecular characterization useful for targeted therapy orientation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) included in early phase clinical trials?
Titel:
24P Is molecular characterization useful for targeted therapy orientation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) included in early phase clinical trials?
Auteur:
Michot, J-M. Camara-Clayette, V. Quivoron, C. Danu, A. Lazarovici, J. Ghez, D. Rossignol, J. Baldini, C. Martin Romano, P. Sarkozy, C. Varga, A. Cotteret, S. Dartigues, P. Massard, C. Ribrag, V.